

NOW CE MARKED FOR 1-MONTH DAPT IN HIGH BLEEDING RISK PATIENTS



Addressing the unmet high bleeding risk (HBR) patient need

Up to

40%

of PCI patients are at high bleeding risk¹

LIMITED EVIDENCE

HBR patients have historically been excluded from stent and drug trials²

COMPLEX


HBR patients appear to have complex disease more often than all-comer patients³

~3x

Greater risk of bleeding events for HBR patients on extended DAPT regimen⁴

Resolute Onyx DES was safe and effective in highly complex HBR patients on 1-month DAPT^{5,6} Onyx ONE Global Study

PRIMARY ENDPOINT MET WITH RESOLUTE ONYX DES (17.1%) NONINFERIOR TO BIOFREEDOM™ DCS (16.9%)⁵



CE MARK based on results from the study, the first prospective, randomised, 1-month DAPT trial comparing a DES to a DES in HBR patients.

Highly complex HBR patient population

Resolute Onyx DES arm (N = 1003)



NO VESSEL OR LESION LIMITATIONS			REAL-WORLD PATIENTS			BROADEST HBR INCLUSION CRITERIA ^{††7}	
B2/C LESIONS	AVERAGE STENTED LENGTH	MOD/SEV CALCIFIED LESIONS	ACS	AF	DIABETES	HBR CRITERIA PER PATIENT	PATIENTS HAVING TWO OR MORE HBR CRITERIA
80%	38 mm	46%	53%	33%	39%	1.6	46%



PART OF THE ONYX ONE MONTH DAPT PROGRAM

The most robust clinical program studying 2700^{***} highly complex HBR patients with 1-month DAPT.

Thin struts and biocompatible polymer promote fast healing and enable short DAPT duration⁸



BioLinX™ polymer is specifically designed for DES.

Single wire design for best-in-class deliverability, conformability, and apposition



Resolute Onyx DES is optimised for your complex clinical practice

1-month DAPT in HBR patients

Diabetes mellitus

In-stent restenosis (ISR)

Multivessel disease

Chronic total occlusions (CTO)

Acute coronary syndrome (ACS)

Total occlusions (TO)

Acute myocardial infarction (AMI)

Left main (LM)

Unstable angina (UA)

Small vessel (SV)

Bifurcation lesions

CE
2797

*Third party brands are trademarks of their respective owners.

¹Primary endpoint does not include TLR.

²ST, MI, and CD were not separately powered endpoints.

³Matching LEADERS FREE inclusion criteria.

⁴Combines Onyx ONE Global Study patients (N = 1996) and Onyx ONE Clear Study patients (N = 752).

⁵Windecker S. Stent Selection for 1-3 Month DAPT: Current Evidence Ongoing Studies. Presented at TCT 2018; San Diego, CA.

⁶Urban P, Meredith IT, Abizaid A, et al. Polymer-free Drug-Coated Coronary Stents in Patients at High Bleeding Risk. *N Engl J Med*. November 19, 2015;373:2038-2047.

⁷Lipiecki J, Brunel P, Morice MC, et al. Biolimus A9 polymer-free coated stents in high bleeding risk patients undergoing complex PCI: evidence from the LEADERS FREE randomised clinical trial. *EuroIntervention*. July 20, 2018;14(4):e418-e425.

⁸Costa F, van Klaveren D, James S, et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. *Lancet*. March 11, 2017;389(10073):1025-1034.

⁹Windecker S, Latib A, Kedhi E, et al. Polymer-based or Polymer-free Stents in Patients at High Bleeding Risk. *N Engl J Med*. March 26, 2020;382(13):1208-1218.

¹⁰Kirtane A, et al. One Month Dual Antiplatelet Therapy in High Bleeding Risk Patients: Primary Results of Onyx ONE Clear. Presented online at ACC 2020.

¹¹Kedhi E, Latib A, Abizaid A, et al. Rationale and design of the Onyx ONE global randomized trial: A randomized controlled trial of high bleeding risk patients after stent placement with 1 month of dual antiplatelet therapy. *Am Heart J*. August 2019;214:134-141.

¹²Roleder T, Kedhi E, Berta B, et al. Short-term stent coverage of second-generation zotarolimus-eluting durable polymer stents: Onyx one-month optical coherence tomography study. *Adv Interv Cardiol*. 2019;15(2):143-150.

Medtronic

Europe
Medtronic Intl. Trading SARL
Tel: 41.21.802.7000

Asia Pacific
Medtronic Intl. Ltd.
Tel: 65.6436.5000

Latin America
Medtronic
Tel: 786.709.4200

[medtronic.com/OnyxOne](https://www.medtronic.com/OnyxOne)

UC202015074 ML ©2020 Medtronic. All rights reserved. Medtronic and the Medtronic logo are trademarks of Medtronic. All other brands are trademarks of a Medtronic company. For distribution only in markets where the Resolute Onyx™ coronary stent has been approved. Not for distribution in the USA, Japan, France, Canada, or Australia. 05/2020